Cardiawave has developed a unique non-invasive ultrasound therapy for the treatment of calcific aortic stenosis.
Our mission is to improve the quality of patient care by offering medical devices for non-invasive therapies.
Discover our job offers!
Aortic stenosis is one of the most common and serious valve disease problems. It is a life-threatening disease caused by the narrowing of the opening of the aortic valve.
most frequent cardiovascular disease in developed countries (1) (2).
In Europe and North America combined, 2.6M patients suffer from symptomatic severe
Aortic valve stenosis, in the population aged 75Y and above. This number will increase to 3M by 2031 (1).
health spending to treat symptomatic aortic valve disease in the United States of America (4).
of severe symptomatic aortic stenosis patients remain untreated in the United States of America (5).
To treat calcific aortic stenosis, Cardiawave has developed a Non-Invasive Ultrasound Therapy (NIUT). NIUT consists in softening the aortic valve, not replacing it. No surgery is required.
Our unique approach could represent both an alternative for patients non eligible for SAVR/TAVR (Surgical Aortic Valve Replacement) and a complementary approach to current procedures to prepare overly calcified aortic valves before the deployment of a TAVR.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 829492.
This project has received funding from the Innov’Up of the Ile-de-France region program under grant agreement No DOS0133065/00.
This project is supported by the French Government, managed by the National Research Agency (ANR) under the program “Investissements d’avenir” with the reference ANR-16-RHUS-0003.
